Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir
(TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency